PFW Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.23M Buy
2,695
+833
+45% +$851K 0.94% 19
2026
Q1
$1.71M Buy
1,862
+13
+0.7% +$13.2K 0.54% 41
2025
Q4
$1.99M Sell
1,849
-74
-4% -$70.8K 0.6% 36
2025
Q3
$1.47M Buy
1,923
+1,078
+128% +$802K 0.43% 49
2025
Q2
$659K Sell
845
-10
-1% -$7.77K 0.2% 80
2025
Q1
$706K Sell
855
-3
-0.3% -$2.5K 0.22% 80
2024
Q4
$662K Buy
+858
New +$710K 0.2% 79
2024
Q2
$784K Sell
866
-116
-12% -$92.8K 0.25% 74
2024
Q1
$764K Buy
982
+16
+2% +$11.4K 0.23% 75
2023
Q4
$563K Buy
966
+60
+7% +$35K 0.18% 84
2023
Q3
$487K Hold
906
0.17% 80
2023
Q2
$479K Buy
+906
New +$380K 0.16% 81
2019
Q3
$777K Buy
+877
New +$97.6K 0.24% 77

Other funds holding LLY

PFW Advisors's LLY Position: Q2 2026 in Review

PFW Advisors increased its Eli Lilly (LLY) stake by 45% in Q2 2026, buying an estimated $851K and bringing the position to 2,695 shares worth $3.23M. The position accounts for 0.94% of the portfolio, ranked #19.

PFW Advisors first reported a position in LLY in Q3 2019 and has held it in 13 quarters since. 961 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • PFW Advisors held 2,695 shares of Eli Lilly worth $3.23M as of Q2 2026.
  • PFW Advisors bought 833 Eli Lilly shares in Q2 2026, an estimated $851K.
  • Eli Lilly made up 0.94% of PFW Advisors's portfolio in Q2 2026, its #19 holding.
  • PFW Advisors first reported a position in Eli Lilly in Q3 2019 and has held it in 13 quarters since.
  • 961 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on PFW Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.